| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-08-21 | Cyprotex (UK) | loan | Harwood Capital (UK) | Loan | ||
| 2013-08-21 | Genmab (Denmark) | capital increase through employee warrant exercises | employees including President & CEO Jan van de Winkel and board member Burton G. Malkiel | Cancer - Oncology | Capital increase | |
| 2013-08-20 | Somantix (The Netherlands) the University of Birmingham (UK) | €1.5 million | grant | European Industrial Doctorate (EU) | Cancer - Oncology | Grant |
| 2013-08-18 | Epigenomics (Germany) | € 5 million | bond financing | Yorkville Advisors LLC (USA) | Diagnostic - Cancer - Oncology | Fundraising |
| 2013-08-17 | Bionor Pharma (Norway) | NOK 7.7 million (€ 0.97 million) | grant | the Research Council of Norway (Norway) | Infectious diseases | Grant |
| 2013-08-09 | Addex Therapeutics (Switzerland) | CHF3.2 million (€2.6 million) | private placement | BVF Partners L.P (USA) - Armistice Capital (USA) - EcoR1 Capital (USA) - board members- executive management | Mental diseases - Psychiatric diseases | Private placement |
| 2013-08-08 | Epistem (UK) | €1.5 million | grant | European Commission’s Seventh Framework Program (FP7) | Diagnostic - Infectious diseases | Grant |
| 2013-08-07 | Telormedix (Switzerland) | €1.77 million | grant | European Eurostars Programme (EU) | Autoimmune diseases - Dermatological diseases | Grant |
| 2013-08-06 | Pluristem Therapeutics (Israel) | $3.3 Million (€2.49 million) | grant | Office of the Chief Scientist (OCS -Israel) | Cardiovascular diseases - Regenerative medicine | Grant |
| 2013-08-01 | ReNeuron (UK) | £1.5 million (€1.7 million) | grant | Technology Strategy Board (UK) | Regenerative medicine - Neurological diseases | Grant |
| 2013-08-01 | Prosensa (The Netherlands) | €6 million | grant | European Commission’s Seventh Framework Program (FP7) | Rare diseases - Neuromuscular diseases | Grant |
| 2013-07-31 | Videregen Cell (UK)Therapy Catapult (UK) NHS Blood and Transplant (UK) Royal Free London NHS Foundation Trust (UK) University College London (UK) | £2million (€2.3 million) | award | Technology Strategy Board (UK) | Regenerative medicine - Respiratory diseases | Grant |
| 2013-07-31 | Summit (UK) | £2.4 million (€2.75 million) | grant | Biomedical Catalyst Fund (UK) | Rare diseases - Neuromuscular diseases | Grant |
| 2013-07-29 | Glycovaxyn (Switzerland) | CHF 5.1 million (€ 4.05 million) | award | Infectious diseases | Grant | |
| 2013-07-29 | Arecor (UK) | award | Infectious diseases | Grant | ||
| 2013-07-26 | Polytherics (UK) | £13.5 million (€15,6 million) | private placement | Imperial Innovations (UK) Invesco Perpetual (UK) Mercia Fund Management (UK) Advantage Enterprise & Innovation Fund (UK) | Private placement | |
| 2013-07-25 | BioInvent International (Sweden) | SEK 23.2 million (€2.7 million) | rights issue | Cancer - Oncology | Fundraising | |
| 2013-07-23 | ROMANE Consortium (France) The consortium includes AB Science, the Brain and Spine Institute (ICM), MIRCen from the Atomic Energy Commission (CEA), the National Institute of Health and Medical Research (INSERM), Imagine Foundation and Skuldtech. | € 8.6 million | grant and repayable avances | Bpifrance (France) | Neurodegenerative diseases | Grant |
| 2013-07-23 | Sage Therapeutics (USA - MA) | $103.5 million | IPO | CNS diseases | IPO | |
| 2013-07-22 | ReNeuron (UK) | £33 million (€38.3 million) | private placement, grant package | Welsh Government (UK) Invesco Perpetual (UK) Abingworth (UK) | Regenerative medicine - Neurological diseases | Private placement |
